Omeros (NASDAQ:OMER) Director Sells $92,650.00 in Stock

Omeros Corporation (NASDAQ:OMER) Director Arnold Hanish sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $18.53, for a total value of $92,650.00. Following the sale, the director owned 5,000 shares in the company, valued at $92,650. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Omeros Stock Down 3.5%

Omeros stock traded down $0.67 during trading hours on Friday, hitting $18.58. The stock had a trading volume of 1,143,548 shares, compared to its average volume of 1,711,871. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of 14.52 and a beta of 2.54. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65. The business’s 50 day simple moving average is $12.48 and its 200-day simple moving average is $11.98.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. Research analysts anticipate that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on OMER shares. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of OMER. State of Wyoming acquired a new position in shares of Omeros in the 4th quarter worth approximately $25,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Omeros during the second quarter worth $32,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros during the fourth quarter worth $33,000. Assetmark Inc. bought a new position in Omeros during the first quarter worth $38,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.